Clinical Trial Update: Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on Cytoplasmic Activated PD-1 CAR T Cells for relapsed/refractory B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Cytoplasmic Activated PD-1 CAR T Cells

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Relapsed Non Hodgkin Lymphoma | Phase 1 | Status: UNKNOWN